ORAMED PHARMACEUTICALS INC. - FORM 10-K - EX-32.1 - CERTIFICATION - November 25, 2015

Attached files

file filename
EX-10.4 - AMENDMENT, DATED JULY 21, 2015, TO CONSULTING AGREEMENTS BY AND BETWEEN ORAMED LTD. AND KNRY, LTD. - ORAMED PHARMACEUTICALS INC.f10k2015ex10iv_oramed.htm
EX-10.12 - AMENDMENT TO EMPLOYMENT AGREEMENT, DATED AS OF JULY 17, 2013, BY AND BETWEEN ORAMED LTD. AND YIFAT ZOMMER - ORAMED PHARMACEUTICALS INC.f10k2015ex10xii_oramed.htm
EX-10.13 - AMENDMENT TO EMPLOYMENT AGREEMENT, DATED AS OF JULY 21, 2015, BY AND BETWEEN ORAMED LTD. AND YIFAT ZOMMER - ORAMED PHARMACEUTICALS INC.f10k2015ex10xiii_oramed.htm
EX-31.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2015ex31i_oramed.htm
EX-32.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2015ex32ii_oramed.htm
EX-10.25 - AMENDMENT TO EMPLOYMENT AGREEMENT, DATED JULY 21, 2015, BETWEEN ORAMED LTD. AND JOSHUA HEXTER - ORAMED PHARMACEUTICALS INC.f10k2015ex10xxv_oramed.htm
EX-10.22 - AGREEMENT AND AMENDMENT NO. 2, DATED APRIL 1, 2015, WITH DR. MICHAEL BERELOWITZ - ORAMED PHARMACEUTICALS INC.f10k2015ex10xxii_oramed.htm
10-K - ANNUAL REPORT - ORAMED PHARMACEUTICALS INC.f10k2015_oramedpharma.htm
EX-31.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k201531ii_oramed.htm
EX-23.1 - CONSENT OF KESSELMAN & KESSELMAN, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - ORAMED PHARMACEUTICALS INC.f10k2015ex23i_oramed.htm
EX-10.5 - AMENDMENT, DATED JULY 21, 2015, TO CONSULTING AGREEMENTS BY AND BETWEEN ORAMED LTD. AND KNRY, LTD. - ORAMED PHARMACEUTICALS INC.f10k2015ex10v_oramed.htm

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

 

In connection with the annual report of Oramed Pharmaceuticals Inc., or the Company, on Form 10-K for the period ended August 31, 2015, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Nadav Kidron, President, Chief Executive Officer and a Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:

 

1.   The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and
   
2.   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: November 25, 2015 /s/ Nadav Kidron 
  Nadav Kidron
President and Chief Executive Officer

 

Stock widget

Investing forum

ORAMED PHARMACEUTICALS INC. Reports